Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. - Wikidata - wikimedia - TriplyDB

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.

http://www.wikidata.org/entity/Q36962460

about

The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis.Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.CD4+T cell specific B7-H1 selectively inhibits proliferation of naïve T cells and Th17 differentiation in experimental autoimmune encephalomyelitis.Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment

P2860

Q33835174-6A62AC09-D699-4091-A3E4-0F972F89CB66 Q37741143-3D1A7217-BDD3-4C67-A017-9BD12233D94E Q38635512-5BB42D82-28D5-4D26-9695-DD5B95E9085F Q38637044-E4DE6F56-3B6C-4F18-AA28-D732CA5A0427 Q38737954-828CBDA9-B542-475A-B76A-B4FCB2C2A4E4 Q38819982-CCF52ED6-B3C3-48AE-ACDE-39E10ED8A300 Q40648999-C3D64A50-9664-4E58-85AB-CAD624061DA4 Q41472948-25B039E2-82AE-4099-8A79-83E5733E4C71 Q41903951-D9434C2C-F72F-4C12-9EAD-B92959B61FDB Q42011685-5E848D62-199E-4A99-856D-884E88BFD472 Q47139579-9184B02F-464D-4085-B4E2-5B83FC962A56 Q47835081-69552D94-73AC-48CB-B242-437ABCE4BA40 Q58580731-3674D25D-5ED0-49E5-9465-A4A973619860

P2860

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.

http://www.wikidata.org/entity/Q36962460

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Expression of programmed cell ...... clinical outcomes in gliomas.

@en

type

label

Expression of programmed cell ...... clinical outcomes in gliomas.

@en

prefLabel

Expression of programmed cell ...... clinical outcomes in gliomas.

@en

P1433

Q36962460-B77DEC56-9CB0-4584-B235-85ECA0F9FF19

P1476

Q36962460-F1FB2EAC-E1F1-40B6-8CE5-45BBE3D88F84

P2093

Q36962460-330DF52E-CDCA-4752-A55B-E855C777A15E

Q36962460-4447EF60-A851-42D0-A3B1-087C855F9DC8

Q36962460-4B125824-0DAF-4005-AF2D-F132754F9B9E

Q36962460-59E4B13A-94F5-4FAE-B992-54EED5BAF062

Q36962460-D5A55691-91A2-4A8E-8BB0-9F6B947FCF30

Q36962460-EBB35F2D-0B96-4822-B7FC-58979DEFFC1B

P2860

Q36962460-00B2EBED-967D-42B4-A84B-A8714729E03A

Q36962460-05B8F5D9-2299-4DEE-AD33-42AB831F6BFD

Q36962460-0FD4E169-112B-488A-AC84-E62C54A55486

Q36962460-163A359C-C504-4607-B5F5-4781D8C1B02E

Q36962460-1F1E6713-2E37-4632-A3FF-D4AAB2DF4EEA

Q36962460-368E4D62-849D-4FD0-B10C-CC0C0C3AACCA

Q36962460-41477252-CDE3-4FDD-ACB9-FB2C212E3C85

Q36962460-41BC8534-3981-4757-97AC-44B89FB830CA

Q36962460-453D874E-3E97-43C0-A5BD-89561C3E515A

Q36962460-45F1D899-7613-4370-8C5B-9CB7BEA59807

P304

Q36962460-CE9C2F3B-1E8E-4794-AACD-B866E9FEEEF0

P31

Q36962460-22E6C623-5E8B-41A7-8149-78D732FEFBC8

P356

Q36962460-B2C5F4FB-2ED8-49B8-AD77-3F0B4D21E233

P407

Q36962460-ADA6E345-BAD3-4159-9BB4-FDFA76F4438A

P433

Q36962460-7A0C7DF2-EEBD-430D-B4B0-1056E70F6015

P478

Q36962460-0B96926C-DA34-4234-9EE7-1E15F359E935

P577

Q36962460-A245AF9C-26F6-48B5-BF21-C58AA06AC6C0

P698

Q36962460-DEC37027-C70C-4EA3-B162-EED6C76F421E

P932

Q36962460-65BA7E2E-6BFE-4F3C-B16E-E2BF1D2FCE48

P356

ONCOTARGET.6884

P1433

P1476

Expression of programmed cell ...... clinical outcomes in gliomas.

@en

P2093

Hua-Dong Chen

http://www.w3.org/2001/XMLSchema#string

Jing Zeng

http://www.w3.org/2001/XMLSchema#string

Qiu-Liang Wu

http://www.w3.org/2001/XMLSchema#string

Su-Xia Lin

http://www.w3.org/2001/XMLSchema#string

Xin-Ke Zhang

http://www.w3.org/2001/XMLSchema#string

Zhi-Hai Zhong

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The 2007 WHO classification of tumours of the central nervous system

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Nivolumab plus ipilimumab in advanced melanoma.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Immunosuppressive networks in the tumour environment and their therapeutic relevance

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

P304

8944-8955

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.6884

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26771840

http://www.w3.org/2001/XMLSchema#string

P932

4891016

http://www.w3.org/2001/XMLSchema#string